Skip to content

Reported August 7, 2025 · Before market open

Revenue estimate$50.0M
EPS estimate$0.49

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.30

Financials

Q2 2025

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$54.7M-251%
Net income-$52.6M-261%
EPS (diluted)-$0.76-40.7%

Balance sheet

See full
Cash & equivalents$144.9M+252%
Total equity$172.1M+118%
Total assets$180.8M+77.9%

Cash flow

See full
Operating cash flow-$53.0M-478%
CapEx$1.0K-99.8%
Free cash flow-$53.0M-446%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$89.04M
P/S4.1×

Profitability

See full
Gross margin89.1%+1.9pp
Operating margin-473.8%+702pp
Net margin-48.2%-21.8pp
FCF margin-446.8%+29,944pp

Returns & leverage

See full
Return on equity-8.3%-3.9pp
Current ratio20.4×+16.2×

Segments

By segment

See full
Reportable--100%

Versus estimates

Ask the moment Whitehawk Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Whitehawk Therapeutics, Inc. Common Stock report Q2 2025 earnings?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Whitehawk Therapeutics, Inc. Common Stock's Q2 2025 revenue and EPS?
Whitehawk Therapeutics, Inc. Common Stock reported revenue of - and diluted EPS of $-0.76 for Q2 2025.
Did Whitehawk Therapeutics, Inc. Common Stock beat estimates in Q2 2025?
Revenue missed the consensus estimate of $50.0M by $50.0M. EPS missed the consensus estimate of $0.49 by $1.25.
Where can I find Whitehawk Therapeutics, Inc. Common Stock's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-105081) directly on SEC EDGAR. The filing index links above go to sec.gov.